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ABSTRACT
Generation of stable transgenic embryonic stem (ES) cell
lines by classic transfection is still a difficult task, requiring
time-consuming clonal selection, and hampered by clonal
artifacts and gene silencing. Here we describe a novel system
that allows construction of lentivectors and generation of
stable ES cell lines with >99% transgene expression within
a very short time frame. Rapid insertion of promoters and
genes of interest is obtained through a modular recombina-
tional cloning system. Vectors contain central polypurine
tract from HIV-1 element and woodchuck hepatitis virus
post-transcriptional regulatory element as well as antibiotic
resistance to achieve optimal and homogenous transgene
expression. We show that the system 1) is functional in
mouse and human ES cells, 2) allows the generation of ES
cells expressing genes of interest under the control of ubiq-
uitous or tissue-specific promoters, and 3) allows ES cells
expressing two constructs through selection with different
antibiotics to be obtained. The technology described herein
should become a useful tool in stem cell research. STEM
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INTRODUCTION
Transgenic embryonic stem (ES) cell lines are important tools
for studying development and cell differentiation, yet the gen-
eration of such lines remains technically difficult and time-
consuming. Gene delivery in ES cells can be achieved by
chemical/mechanical transfection or by viral transduction [1].
Establishment of stable transgenic ES cell lines has so far
mainly been achieved through electroporation [2, 3]. However,
this technique is time-consuming, requiring clonal selection,
analysis of antibiotic-resistant clones for transgene expression,
and the use of several transgene-expressing clones for follow-up
experiments to exclude clonal artifacts.
Retroviral vectors have been used by several groups to
achieve stable transgene expression in ES cells [4–7]. However,
a major limitation of retroviral vectors is gene silencing that
occurs during propagation [8] and differentiation [9] of trans-
duced cells. More recently, lentivectors have been successfully
used to transduce ES cells [10–12]. Current generations of
lentivectors are self-inactivating [13] and, therefore, compatible
with a high biosafety level. Although silencing in ES cells has
also been reported with lentivectors [14], it appears to occur to
a lesser extent than with traditional retroviral vectors [10, 15].
Thus, lentivectors are promising tools for engineering geneti-
cally modified ES cell lines. However, there are several limita-
tions for a widespread use of lentivectors in ES cell research,
including 1) the cloning flexibility provided by presently avail-
able lentivectors is poor and 2) the transduction efficiencies of
ES cells with lentivectors are only in the range of 20%–80% [1].
Thus, selection strategies to obtain homogenously transgene-
expressing cell lines are necessary. So far, the most promising
tools have been bicistronic lentivectors [16, 17], which allow the
coexpression of a gene of interest and a selection marker under
the control of the same promoter. However, this approach has
two major limitations: 1) transgene expression levels are poorly
predictable [18] and 2) the establishment of stable ES cell lines
using tissue-specific promoters is not possible, because the
selection marker will not be expressed in undifferentiated cells.
The use of tissue-specific promoters driving the expression
of reporter genes is of particular interest to mark subsets of ES
cell progeny. This approach can be used to monitor ES cell
differentiation [19], and it is a powerful tool for purifying cells
of a particular lineage [20]. However, due to limitations men-
tioned above, generation of such cell lines remains a technical
challenge.
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In this article we describe a novel lentiviral system for
generating stable ES cell lines that overcomes many of the
limitations observed with previously available lentivectors. We
demonstrate rapid generation of stable ES cell lines expressing
transgenes at various levels using different ubiquitous promot-
ers. We also show monitoring of ES cell differentiation by cell
type-specific expression of reporter genes.
MATERIALS AND METHODS
Reagents
Reagents and their sources were as follows: R4–R2 DNA cas-
sette and pLenti6/BLOCK-iT-DEST, pDONR221, and
pDONRP4-P1R vectors (Invitrogen, Carlsbad, CA, http://www.
invitrogen.com); pWPT-GFP vector was kindly provided by
Drs. P. Salmon and D. Trono (Department of Microbiology,
Faculty of Medicine, Geneva University, Switzerland);
pEGFP-N1 plasmid [BD Biosciences (San Diego, http://www.
bdbiosciences.com)/Clontech (Palo Alto, CA, http://www.
clontech.com)]; the pGEM-T Easy plasmid (Promega, Madi-
son, WI, http://www.promega.com); T1 -tubulin and the
Synapsin1 promoters were kindly provided by Freda Miller
(Hospital for Sick Children, University of Toronto, Canada)
[21] and by James Uney (University Research Centre for Neu-
roendocrinology and Medical Research Council, Centre for Syn-
aptic Plasticity, University of Bristol, Bristol, U.K.) [22], re-
spectively; and the monomeric red fluorescent protein 1
(referred to as RedFP in this report) was kindly provided by
Roger Tsien (Howard Hughes Medical Institute, University of
California at San Diego, San Diego) [23]. The murine CGR8 ES
cell line was from the European Collection of Cell Culture; the
human H1 ES cell line was from Wicell Research Institute Inc.;
the murine D3 ES cell line was provided by Reinhard Korn
(AnTeq AG, Basel, Switzerland); the stromal bone marrow MS5
cell line was provided by Katsuhiko Itoh (Department of Clin-
ical Medical Biology, Kyoto University, Kyoto, Japan) [24]; cell
culture media, fetal bovine serum, serum replacement, penicil-
lin, streptomycin, N2 supplement, nonessential amino acids,
sodium pyruvate, and neomycin were from Gibco (Grand Is-
land, NY, http://www.invitrogen.com); basic human fibroblast
growth factor, blasticidin, and Gateway clonase enzymes were
from Invitrogen.
Vector Constructions
A PCR product flanked by R4–R2 recombination sites and
containing the ccdB and chloramphenicol resistance coding
sequences was ligated into SpeI-SacII-cleaved pLenti6/
BLOCK-iT-DEST lentivector. The woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE) from pWPT-
GFP was ligated 3 of the R4–R2 cassette into the EcoRI-
cleaved lentiviral construct. The cPPT element from pWPT-
GFP was ligated 5 of the R4–R2 cassette into NheI-SpeI-
cleaved lentiviral construct. We named the resulting lentiviral
construct 2K7bsd. To generate the 2K7neo lentivector, the blas-
ticidin resistance coding sequence and the bacterial EM7 pro-
moter were replaced by the neomycin resistance coding se-
quence. To generate entry vectors, the different promoters and
genes of interest were cloned into pDONRP4–P1R and
pDONR221, respectively, using the Gateway BP clonase en-
zyme mix. The resulting entry vectors were then recombined
into 2K7bsd or 2K7neo lentivectors using the Gateway LR plus
clonase enzyme mix.
Cell Cultures
The CGR8 and D3 ES cells were maintained in BHK-21 me-
dium supplemented with 10% fetal calf serum, L-glutamine,
nonessential amino acids, sodium pyruvate, penicillin and strep-
tomycin, and leukemia inhibitory factor. The H1 ES cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)/
F-12 medium supplemented with 20% serum replacement, L-
glutamine, nonessential amino acids, and 4 ng/ml human basic
fibroblast growth factor. CGR8 ES cells were cultured on gel-
atin-coated dishes. D3 ES cells were cultured on irradiated
mouse embryonic fibroblasts (MEFs) or STO mouse fibroblasts.
H1 ES cells were cultured on irradiated mouse embryonic
fibroblasts.
ES Cell Differentiation
Neuronal differentiation was carried out as described [25].
Briefly, irradiated MS5 cells (1.75  105 per well) were seeded
in 6-well plates. The next day, CGR8 cells (0.6 103 to 3 103
cells per well) were plated on the MS5 layer in complete
DMEM supplemented with nonessential amino acids, 2-mercap-
toethanol, and 15% knockout serum. Five days later, cells were
then trypsinized and seeded onto polyornithin-coated 6-well
plates in complete DMEM supplemented with N2 supplement
and human basic fibroblast growth factor. Embryoid bodies
were generated by the hanging drop method as described [26].
Lentivector Production and Transductions
The lentivector particles were produced by transient transfection
in 293T cells as previously described [27]. The lentivector-
containing supernatant was collected after 72 h, filtered through
0.45-m pore-sized polyethersulfone membrane, and concen-
trated 120-fold by ultracentrifugation (50,000g, for 90 minutes
at 4°C). The pellet was resuspended in complete cell culture
medium and subsequently added to the target cells. Titers of the
concentrated lentivector were estimated by HeLa cell transduc-
tion and ranged from 5  107 to 108 transducing units per
milliliter. The multiplicity of infection ranged from 1.2 104 to
2.5 104 for transduction of murine D3 and CGR8 ES cells and
from 15 to 30 for transduction of human H1 ES cells. CGR8 ES
cells (104 cells per well) were seeded onto gelatin-coated 6-well
plates 1 day prior to transduction. Two days later, cells were
split in 85-mm gelatin-coated culture dishes. D3 ES cells (2 
104) were transduced in suspension on gelatin-coated 6-well
plates and 1 day later were split onto the blasticidin-resistant
STO feeder layer. H1 ES cell aggregates (5  105 cells) were
transduced in suspension onto the MEF feeder layer or the
blasticidin-resistant STO feeder layer. Three days after trans-
duction, blasticidin or neomycin was added to the culture me-
dium of ES cells. Blasticidin selection was maintained for 6
days on murine ES cells or 21 days on human H1 ES cells, and
neomycin selection was maintained for 10 days for murine
CGR8 ES cells. The antibiotics were used as follows: CGR8
cells, 7.5 g/ml blasticidin or 400 g/ml neomycin; D3 cells, 10
g/ml blasticidin; and H1 cells, 10 g/ml blasticidin.
616 Stable ES Cell Lines Through Modular Lentivectors
Self-inactivation of Lentivectors in ES Cells
We verified whether transduced cell lines were indeed unable to
generate infectious lentiviral particles. A stable CGR8 murine
ES cell line transduced with 2K7bsd EF1-S/GFP and nontrans-
duced CGR8 cells were seeded at a density of 5  105 cells per
85-mm dish and cultured for 72 hours up to 70% confluency
without changing the medium. The supernatant was then col-
lected and filtered through a 0.45-m pore-sized polyethersul-
fone membrane, and 1 or 2 ml were incubated with 104 HeLa
cells. Experiments were performed in triplicates. After 72 hours
of incubation, no enhanced green fluorescent protein (eGFP)
expression could be detected in HeLa cells incubated in either
supernatant, demonstrating that 2K7-transduced ES cell lines do
not release infectious lentiviral particles into the medium.
Immunofluorescence Microscopy
Immunofluorescence was carried out according to standard
techniques. In brief, ES cells were grown on glass coverslips
coated with either an MS5 feeder layer or polyornithin in 6-well
plates. Cells were fixed with 2% paraformaldehyde for 30
minutes, washed with Hanks’ balanced salt solution (HBSS),
and permeabilized with 0.5% (vol/vol) Triton X-100 for 30
minutes. Cells were then exposed to primary antibodies over-
night at 4°C. After two washes in HBSS containing 1% serum
(blocking buffer), cells were stained with secondary antibodies
at room temperature for 1 hour (1:1000 dilution in blocking
buffer). Cell nuclei were stained with 1 g/ml 4,6-diamidino-
2-phenylindole (DAPI) for 10 minutes. Visualization analysis
took place on a Zeiss axioplan microscope equipped for epiflu-
orescence. The dilutions for the primary antibodies in blocking
buffer were as follows: mouse monoclonal antinestin antibody
(1/2500, Chemicon, Temecula, CA, http://www.chemicon.com),
rabbit polyclonal anti-synapsin antibody (1/1000, Chemicon),
and rabbit polyclonal anti-class III -tubulin antibody (1/1000,
Covance, Princeton, NJ, http://www.covance.com). For second-
ary detection, Alexa Fluor 488 or 555 conjugates were used
(1/1000, Molecular Probes Inc., Eugene, OR, http://probes.
invitrogen.com). Rat primary hippocampal neurons were used
as positive controls for class III -tubulin and synapsin immu-
nostaining. Glial cells from mouse hypothalamic median emi-
nence were used as positive controls for nestin immunostaining.
For negative controls, immunostaining was performed without
first antibody.
Quantitative Analysis of Cells Expressing
Fluorescent Proteins
Feeder cell-independent eGFP-transduced cells (CGR8) were
analyzed by flow cytometry using a FACScan (BD Bio-
sciences). Quantification of expression of fluorescent proteins in
feeder cell-dependent D3 murine ES cells (which were cultured
in the presence of RedFP-positive feeder cells) were quantified
by direct cell counting using a fluorescence microscope.
For flow cytometry analysis, H1 ES cells were rinsed with
phosphate-buffered saline, incubated in trypsin-EDTA for 20
minutes, and passed through a 60-m cell strainer (Falcon).
Cells were labeled on ice with TRA-1–85 antibody (Develop-
mental Studies Hybridoma Bank, Iowa City, IA, http://www.
uiowa.edu/dshbwww) at a 1:100 dilution, rinsed, and incu-
bated with a goat anti-mouse-PE secondary antibody (DAKO,
Glostrup, Denmark, http://www.dako.com) at a 1:80 dilution.
Cells were analyzed with a FACScan (BD Biosciences).
For the studies investigating the activity of the T1 -tu-
bulin/RedFP and Synapsin1/eGFP constructs during neuronal
differentiation of CGR8 cells, fluorescence intensity of eGFP
and RedFP in a given cell was quantified using the Metamorph
software.
RESULTS
Construction of the 2K7 Lentivector
We intended to construct a lentivector with the following prop-
erties: 1) easy insertion of promoters and genes of interest; 2)
possibility to select transduced cells through antibiotics; and 3)
high level transgene expression. To construct such a vector, we
modified a commercially available self-inactivating lentiviral
vector (pLenti6/BLOCK-iT-DEST, Invitrogen). We replaced its
recombination site with a double recombination cassette
(R4–R2 Gateway cassette), which allows the recombination of
a promoter and a gene of interest from two separate entry
vectors. To enhance transgene expression, the WPRE was in-
serted 3 to the recombination site [28]. To increase the number
of integrated transgenes upon transduction, the central polypu-
rine tract from HIV-1 (cPPT) was inserted 5 to the recombi-
nation site [29]. We named the vector obtained through this
procedure 2K7. As the pLenti6/BLOCK-iT-DEST vector con-
tained a blasticidin resistance, the first version of 2K7 also
contained this resistance and is therefore specified as 2K7bsd. To
allow double transduction and selection, we also constructed a
version of the vector where the blasticidin resistance was replaced
by a neomycin resistance. This vector will be referred to as 2K7neo.
A general scheme of the 2K7 vector is shown in Fig. 1.
Figure 1. Schematic of the 2K7 lentivector and the insertion of
promoters and genes of interest. The recombination site of pLenti6
BLOCK-iT-DEST was replaced with a cassette flanked by the R4 and
R2 recombination sites, thus enabling the spatially controlled insertion
of both a promoter and a gene of interest from two separate entry
vectors. Arrows indicate recombination events between the different
elements, resulting in the expression construct. 3 to the recombination
site, a SV40 promoter drives the expression of an antibiotic resistance.
The WPRE and cPPT element were inserted into the vector backbone to
increase transgene expression and copy number of the integrated trans-
gene, respectively. Finally, a version of the vector containing a neomy-
cin instead of the blasticidin resistance was generated. This allows
selection for the expression of two different constructs in the same cell.
(A): Schematic representation of two entry vectors and the recipient
2K7 lentivector; arrows show recombination events that allow direc-
tional cloning. (B): Resulting expression lentiviral construct.
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Constitutive Expression of eGFP in Mouse and
Human ES Cells
We first transduced the feeder cell-independent CGR8 murine
ES cell line with the 2K7bsd vector. We used three different
lentiviral constructs. All three contained eGFP as the gene of
interest but under the control of three different ubiquitous pro-
moters: a 590-basepair (bp) human cytomegalovirus (CMV)
immediate early promoter, a 1264-bp human EF1- promoter,
and a 260-bp, intron-less fragment of the human EF1- pro-
moter [30]. Throughout the text, these promoters will be re-
ferred to as CMV, EF1-, and EF1-S, respectively. Three days
after transduction, approximately 30–50% of CGR8 cells were
eGFP-positive. Transduced cells were subsequently subjected to
blasticidin (7.5 g/ml) selection for 6 days. eGFP expression
after blasticidin selection was analyzed by fluorescence micros-
copy and by flow cytometry (Figs. 2A–2E). All three promoters
led to eGFP expression, but expression levels were markedly
different. The CMV promoter led to relatively low levels, the
EF1-S promoter to intermediate levels, and the EF1- pro-
moter to high levels of eGFP expression. Quantitative analysis
by flow cytometry demonstrated that, under the control of the
long and the short forms of the EF1- promoter, eGFP was
expressed in over 99% of CGR8 cells but, under the control of
the CMV promoter, only in approximately 95% of cells. Once
blasticidin selection was terminated, expression levels for all
three promoters were well maintained over time in culture, even
in the absence of the antibiotic. For one of the cell lines
(EF1-S/eGFP), we performed quantitative analysis: flow cy-
tometry showed that over 99% of CGR8 were still eGFP-
positive with similar mean fluorescence intensity after 30 days
in culture (Figs. 2F, 2G). Thus, as described before for other
lentivectors [10], integration of the 2K7 vector in undifferenti-
ated mouse ES cells is stable and maintained over a prolonged
period. These results also suggest that it is not necessary to
maintain blasticidin selection beyond 6 days after transduction
to maintain a pure population of transduced cells.
Although transgene silencing was not detectable in undif-
ferentiated cells, it might occur during ES cell differentiation.
Thus, we wondered whether eGFP fluorescence was maintained
during neuronal differentiation of the transduced CGR8 cell
lines described above. We induced neuronal differentiation by
culturing EF1-/eGFP-transduced CGR8 cells on a layer of
MS5 cells followed by replating and culture on polyornithin-
coated dishes for 4 days (as described in Materials and Meth-
ods). As shown in Figures 3A and 3C, all cells remained
eGFP-positive during neuronal differentiation. Differentiated
neurons were identified by immunostaining with an anti-3-
tubulin antibody (Fig. 3B). The overlay of eGFP fluorescence
and anti-3-tubulin immunostaining (Fig. 3D) demonstrates that
a substantial fraction of cells were differentiated towards neu-
rons. Note that there is no apparent difference in eGFP fluores-
cence intensity between 3-tubulin-positive and -negative cells.
Similar results were obtained with CMV/eGFP-transduced and
EF1-S/eGFP-transduced CGR8 cells (data not shown).
We next studied the transduction of feeder cell-dependent
ES cell lines. Two different approaches were chosen for the
Figure 2. eGFP expression under the control of different ubiquitous
promoters in mouse embryonic stem (ES) cells. The feeder cell-inde-
pendent CGR8 mouse ES cell line was transduced with different 2K7bsd
lentiviral constructs to express eGFP under the control of different
ubiquitous promoters. Three days after transduction, undifferentiated
cells were submitted to blasticidin selection (7.5 g/ml) for 6 days.
Fluorescence images of nontransduced (A) and stably transduced un-
differentiated CGR8 cells expressing eGFP under the control of CMV
(B), EF1-S (C), and EF1- (D) promoters. Exposure times were 2000
ms for (A–C) and 300 ms for (D). (E): flow cytometry analysis of eGFP
expression under the control of CMV (blue), EF1-S (red), and EF1-
(green) promoter; untransduced cells are shown in black. (F, G): Bar
graph showing, respectively, percentage of eGFP-positive cells and
mean fluorescence intensity of EF1-S/eGFP-transduced CGR8 cells,
after accomplished blasticidin selection (day 0) and after 30 days in
culture without blasticidin (day 30). Scale bar: 50 m.
Figure 3. eGFP expression is maintained during neuronal differentia-
tion of murine embryonic stem (ES) cells. EF1-/eGFP-transduced
CGR8 cells were differentiated towards neurons by coculture on the
mouse bone marrow MS5 cell line for 5 days, followed by replating and
culture on polyornithin-coated dishes for 4 days. Cells were then im-
munostained with anti-3-tubulin antibodies. (A): Phase contrast; (B):
3-tubulin staining (red); (C): eGFP fluorescence (green); (D): merge.
Note that both, 3-tubulin-positive and 3-tubulin-negative cells ex-
press eGFP. Scale bar: 50 m.
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mouse D3 cells and the human H1 cells. D3 cells were trans-
duced with the EF1-/eGFP vector in the absence of feeder cells
and subsequently cultured and subjected to blasticidin selection
on a STO feeder cell line (Figs. 4A, 4B). The STO cells had
been, in a first step, transduced with a lentivector expressing a
red fluorescent protein, RedFP (mRFP1, [23]) and a blasticidin
resistance. Thus, feeder cells were red, and transduced D3 ES
cells were green. We then evaluated the percentage of eGFP-
positive D3 cells by counting eGFP-positive cells (see Materials
and Methods). Over 99% of D3 cells were eGFP-positive (data
not shown).
We next investigated the use of the 2K7 vector for the
transduction of human ES cells based on protocols similar as
described above. Blasticidin-resistant STO feeder cells and H1
cells were cocultured and incubated for 24 hours with the
EF1-S/eGFP lentivector. Days 3–24 after transduction, cells
were subjected to blasticidin selection. This selection did not
lead to a depletion of feeder cells. Within the H1 colonies, areas
of necrosis appeared between 2 and 5 days after initiation of
antibiotic selection, followed by an enrichment in eGFP-positive
H1 cells. H1 ES cells were subsequently passaged on freshly
irradiated blasticidin-resistant STO feeder cells (transduced with
empty 2K7bsd vector, that is no expression of a fluorescent
protein). Colonies of H1 ES cells containing almost exclusively
eGFP-positive cells could be observed after 2 weeks of selection
(Figs. 4C, 4D). Flow cytometry analysis was performed after 3
weeks of selection. Cells were immunostained with the anti-
human TRA1–85 antibody [31] to distinguish human ES cells
from the feeder cells, and over 95% of TRA1–85-positive cells
were also eGFP-positive (Fig. 4F). In addition, we developed a
protocol that allows selection on primary MEFs, which are more
commonly used as feeder cells for human ES cells. As MEF and
human ES cells are cotransduced, they also become eGFP-
positive and blasticidin-resistant. As opposed to the results
shown in Figures 4C and 4D, cells were not passaged, and
feeder cells therefore remained fluorescent (Figs. 4G, 4H).
Thus, feeder cell-dependent human and mouse ES cells can
be efficiently transduced and blasticidin-selected to obtain trans-
gene-expressing cells almost exclusively.
Neuron-Specific Transgene Expression During ES
Cell Differentiation
We next investigated whether the 2K7 vector was able to drive
tissue-specific transgene expression. For this purpose, we gen-
erated stable CGR8 cell lines with lentivectors containing eGFP
under the control of neuron-specific promoters: 1) the T1
-tubulin promoter, active during early neuronal differentiation
and after neuronal injury [21], and 2) the Synapsin1 promoter,
active in more mature neurons and marking the establishment of
synapses [22]. Both promoters have been successfully used in
viral vectors to drive tissue-specific transgene expression [32,
33]. ES cell differentiation was induced by coculture on MS5
cells (Figs. 5A–5C, 5E, 5F) to obtain a high yield of neurons
[25] or by formation of embryoid bodies to obtain a mixed cell
population, including neurons (Fig. 5D). The activity of the
neuron-specific promoters was monitored by the appearance of
green fluorescence, and cells were characterized by immunola-
beling using anti-3-tubulin antibodies or antisynapsin antibod-
ies (neurons) and antinestin antibodies (neuronal precursors).
Under the control of the T1 -tubulin promoter, eGFP
expression appeared at day 3 of differentiation on MS5 cells. In
most 3-tubulin-positive neurons, the activity of the T1 -tu-
bulin promoter (as evidenced by green fluorescence) is present
(Fig. 5A). An overlay of the same field with 4,6-diamidino-2-
phenylindole (DAPI) staining to visualize all cells (Fig. 5B),
shows that most 3-tubulin-negative cells are also eGFP-nega-
tive (i.e. the T1 -tubulin promoter is not active). However,
nestin-positive neuronal precursors (which are mostly 3-tubu-
lin-negative, data not shown) occasionally also displayed activ-
ity of the T1 -tubulin promoter (Fig. 5C). This corroborates
data from the literature suggesting that the T1 -tubulin pro-
moter activity precedes the one of the 3-tubulin promoter and
partially overlaps with the activity of the nestin promoter [20].
We also differentiated the T1 -tubulin/eGFP-transduced cells
toward embryoid bodies to study whether T1 -tubulin pro-
moter activity remains neuron-specific even in a heterogeneous
cell population; in this model, eGFP expression also correlated
with 3-tubulin staining (Fig. 5D).
Under the control of the Synapsin1 promoter, eGFP fluo-
rescence first appeared at day 5 of differentiation on MS5 cells.
It was present in a subset of 3-tubulin-positive neurons (Fig.
5E) and correlated with synapsin immunoreactivity (Fig. 5F).
Figure 4. Transduction of feeder cell-dependent mouse and human
embryonic stem (ES) cells by the 2K7 vector. Undifferentiated mouse
D3 and human H1 ES cells were transduced with a 2K7bsd lentiviral
construct to express eGFP under the control of the EF1- promoter. D3
ES cells were transduced and subsequently submitted to blasticidin
selection for 6 days on STO feeder cells expressing a red fluorescent
protein (RedFP) and blasticidin resistance. H1 human ES cells were
transduced with a 2K7bsd vector containing eGFP under the control of
the EF1-S promoter and were cultured and submitted to blasticidin
selection on a blasticidin-resistant STO feeder layer for 3 weeks. Alter-
natively, H1 human ES cells were transduced on an MEF feeder layer
and subsequently submitted to blasticidin selection. (A, B): Phase con-
trast and fluorescence imaging of transduced D3 ES cells (green) on
STO feeder layer (red). (C, D): Phase contrast and fluorescence imaging
of transduced H1 ES cells (green) on STO feeder cells. (E): Flow
cytometry analysis with the pan-human TRA-1–85 antibody allows
discrimination between human H1 ES cells (upper left quadrant) and
STO feeder cells (lower left quadrant). (F): After 3 weeks of antibiotic
selection, 95% of H1 human ES cells are eGFP-positive (upper right
quadrant). (G, H): Phase contrast and fluorescence imaging of trans-
duced H1 ES cells (green colony) on MEF feeder cells (also green).
Scale bars: 100 m.
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We next wanted to monitor the emergence of neurons within
embryoid bodies (EBs). There was a marked autofluorescence
of the cell culture medium and of cell debris in the green
emission range; thus eGFP fluorescence gave only poor results
with live imaging of embryoid bodies (data not shown). We
therefore transduced CGR8 cells with a T1 -tubulin/RedFP
vector and monitored the in vivo appearance of red fluorescence
within the embryoid body. Six days after plating, spots of red
fluorescence appeared at the margin of the EB and progressively
enlarged over time. The RedFP-positive regions of the EB were
characterized by bundles of parallel oriented cells. The red
fluorescence remaining localized to these bundles over time in
culture. Figure 6 shows phase contrast (6A–6E) and fluores-
cence (6F–6J) images of the same region of an EB between days
10 and 14 after plating. Thus, the T1 -tubulin/RedFP con-
struct allowed monitoring of the emergence of neurons within
the EB and defining of morphologically distinct regions as sites
of neurogenesis.
Two-Color Monitoring of Neuronal
Differentiation Steps
We next investigated the temporal relationship of T1 -tubulin
and Synapsin1 promoter activation during neuronal differentia-
tion of ES cells. For this purpose, we used 2K7 vectors with two
different antibiotic resistances, namely 2K7bsd and 2K7neo,
which allowed us to engineer ES cells homogeneously express-
ing two constructs through double antibiotic selection. We gen-
erated a CGR8 cell line with RedFP expression controlled by the
T1 -tubulin promoter and eGFP expression controlled by the
Synapsin1 promoter. After 4 days of coculture with MS5 cells,
cell clusters expressing RedFP were visible, whereas almost no
eGFP expression was observed (Figs. 7A–7C). After 7 days,
abundant clusters of cells expressing both RedFP and eGFP
were found (Figs. 7D–7F). To investigate the relative activities
of the T1 -tubulin and the Synapsin1 promoters, we quanti-
fied RedFP and eGFP fluorescence at days 4 and 7 of coculture
on the MS5 feeder layer using the Metamorph software (Fig.
7G). This analysis yielded interesting results as follows: 1) the
differentiation state of cells, as judged by the relative expression
of RedFP over eGFP expression, was astonishingly homoge-
neous in a given cluster (a linear regression of data shown in
Fig. 7G yielded r values of .88 and .95 for days 4 and 7,
respectively), and 2) during neuronal differentiation, ES cells
first activate the T1 -tubulin promoter, followed by activation
of the Synapsin1 promoter. These experiments demonstrate that
two-color monitoring with different promoter/reporter con-
structs is a powerful tool to follow neuronal differentiation of
ES cells.
DISCUSSION
In this report we describe a novel system to rapidly generate
transgenic ES cell lines using lentivectors based on recombina-
tional cloning technology. This technology allows the insertion
of both promoters and genes of interest in a single recombina-
tion reaction. After antibiotic selection, mouse and human ES
cell lines expressing transgenes of interest with a high degree of
purity and stability are obtained.
Recombinational Cloning into Lentivectors
Lentivectors are large plasmids and offer only limited flexibility
for cloning with restriction enzymes. Alternatives to restriction
Figure 5. eGFP expression driven by neuron-specific promoters. Mu-
rine CGR8 embryonic stem (ES) cells transduced with various promot-
er/eGFP constructs were differentiated either towards neurons on MS5
cells for 5 (A–D) or 7 days (E), or towards embryoid bodies for 12 days
after plating (F). Differentiated cells were analyzed for eGFP expression
by direct fluorescence (green) and for different neuronal markers by
immunofluorescence (red). (A): T1 -tubulin/eGFP-transduced cells
immunostained with a 3-tubulin antibody (red). (B): Same picture as
(A), but overlaid with 4,6-diamidino-2-phenylindole staining (blue) to
demonstrate the presence of non-neuronal, eGFP-negative cells. (C):
T1 -tubulin/eGFP-transduced cells immunostained with a nestin an-
tibody (red); (D): embryoid body, derived from T1 -tubulin /eGFP-
transduced cells, immunostained with a 3-tubulin antibody. (E): Syn-
apsin1/eGFP-transduced cells immunostained with a 3-tubulin
antibody; (F): Synapsin1/eGFP-transduced cells immunostained with a
synapsin antibody (red). Scale bars: (A–E): 100 m; (F): 50 m.
Figure 6. Live monitoring of T1 -tubulin promoter driven expres-
sion of red fluorescent protein in embryoid bodies. A CGR8 embryonic
stem (ES) cell line expressing a red fluorescent protein (RedFP) driven
by the T1 -tubulin promoter was used to generate embryoid bodies
(EBs). Several days after plating of the EBs, regions at the margins of
the EB show bundles of cells positive for red fluorescent protein.
Pictures of the same region of an EB were taken every 24 hours. (A–E):
Phase contrast imaging. (F–J): RedFP (red). Time points (after plating
of the EBs): (A, F): day 10; (B, G): day 11; (C, H): day 12; (D, I): day
13; and (E, J): day 14. Scale bar: 500 m.
620 Stable ES Cell Lines Through Modular Lentivectors
cloning are therefore particularly interesting for lentivectors.
Recombinational cloning uses enzymes recognizing sequences
that are virtually absent from the mammalian genome and from
most vectors. In a single-step recombination process, a DNA
sequence flanked by recombination sites is replaced by a se-
quence of interest also flanked by recombination sites [34]. In
the context of lentivectors, this has very relevant advantages
over restriction cloning as cloning efficiency is invariably high
(in the range of 80%–100%), and there are virtually no cloning
site incompatibilities.
Another advantage is the possibility to reliably insert two
sequences of interest in a defined order into the target vector in
a single recombination reaction. For this purpose, we decided to
use the Gateway cloning system, which allows multisite recom-
binational cloning, such as directional cloning of both a pro-
moter and a gene of interest into the target vector [34] with
virtually no limitation in their combination. Thus, recombina-
tional cloning technology provides a very high flexibility that
cannot be reached with restriction cloning.
Other groups have been using recombinational cloning di-
rectly in commercially available lentivectors (Gateway Tech-
nology; Invitrogen, [35–39]). However, the vectors used in these
studies lack elements that have been shown to be crucial for
optimal transgene expression, in particular WPRE and cPPT
[28, 29, 40]. We thus incorporated WPRE and cPPT elements in
the backbone of the 2K7 vector; this resulted in greatly en-
hanced transgene expression up to levels comparable to the most
advanced lentivectors (data not shown).
Selection of Transduced ES Cells
Upon lentiviral transduction, approximately 20%–80% of ES
cells are transduced [1]. Thus, methods of selection are neces-
sary to obtain a pure population of transduced cells. One poten-
tial approach is to use bicistronic lentivectors, containing both a
gene of interest and a selection marker under the control of the
same promoter. However, their use is limited, because protein
expression remains poorly predictable [18], and tissue-specific
promoters cannot be used, because the selection marker will not
be expressed in undifferentiated cells.
In the 2K7 lentivector, the antibiotic resistance is under the
control of a ubiquitous promoter, which ensures its expression
independently from the promoter used to drive the expression of
the gene of interest. In our hands, this approach is extremely
useful for work with ES cells, because: 1) more than 99% of
transduced murine ES cells and more than 95% of transduced
human ES cells expressed the transgene after antibiotic selec-
tion, and 2) even if transgene expression was driven by a highly
tissue-specific promoter (e.g. Synapsin1), antibiotic selection
could be performed in undifferentiated cells.
The ES cell population obtained after antibiotic selection of
2K7-transduced cells is polyclonal. We consider this as an
advantage, because artifacts due to clonal selection are avoided.
Indeed, both the sites of 2K7 insertion and the number of copies
per cell are expected to differ from one cell to another [10]. We
have not attempted to measure the average number of vector
copies per cell; however, based on our experimental conditions,
several copies per cell are likely [10]. Given the polyclonal
nature of our transduced lines, possible gene disruptions by
transgene insertion should not have an impact on the behavior of
the cell population. And indeed, we have not observed altered
cell growth or differentiation in transduced lines.
2K7 Lentivector as a Tool for Controlled and
Targeted Gene Expression
Using our system, we compared the efficiency of three ubiqui-
tous promoters in undifferentiated CGR8 murine ES cells. Ac-
tivity levels were low for the CMV promoter, intermediate for
the EF1-S promoter, and high for the EF1- promoter. Be-
cause these promoters can be easily combined with a gene of
interest, it is possible to rapidly generate different cell lines
expressing a transgene at different levels.
Lentivectors have shown efficient tissue-specific transgene
expression upon injection in animals [32, 33]. Here we demon-
strate that, using the 2K7 lentivector with tissue-specific pro-
moters, transgene expression specific for cell type and cellular
state of differentiation can be obtained in ES cells. The speci-
ficity of the promoters was maintained in this system as dem-
onstrated by: 1) the good correlation between immunostaining
and reporter gene expression (Fig. 6F) and 2) the corroboration
between our observations in ES cells and published data ob-
tained in transgenic animals (see for example the temporal
relationship of nestin and 3-tubulin expression with the activ-
ity of the T1 -tubulin promoter in Figs. 6B, 6C, and in Ref.
20). This is of particular interest in the field of ES cell research,
Figure 7. Double transduction of murine embryonic stem (ES) cells to
study the activity of two neuronal promoters. CGR8 cells were trans-
duced with two lentiviral constructs to drive the expression of a red
fluorescent protein (RedFP) by the T1 -tubulin promoter (neomycin
resistance) and eGFP by the Synapsin1 promoter (blasticidin resistance).
After double antibiotic selection, cells were cocultured on a MS5 feeder
layer for four (A–C) or seven (D–F) days. (A) and (D): Red fluorescent
protein (red); (B, E): eGFP (green); (C, F): merge. After 4 days of
differentiation, red fluorescence is already present, whereas almost no
eGFP is detectable (A–C). After 7 days of differentiation, most cells
present red and green fluorescence at different intensities (D–F). (G):
Analysis of red (x-axis) and green (y-axis) fluorescence intensities of 13
randomly chosen cells from (C, F). The x- and y-axis values are
arbitrary fluorescence units. The position of the cells on the graph
indicates their relative state of maturation. Dotted lines are linear re-
gressions. Scale bars: 50 m.
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because it allows the targeted expression of a transgene of
interest in a given cell type or at a given differentiation stage.
Two-Color Live Monitoring of ES
Cell Differentiation
Single-color life monitoring of ES cell differentiation has been
performed previously. It was considered a powerful tool for
studying the promoter activation during neuronal differentiation
and also an efficient tool for monitoring strategies to direct ES
cell differentiation [3]. The availability of the 2K7neo and the
2K7bsd vectors allowed us to go further. Double transduction
followed by double antibiotic selection permitted two-color
monitoring through two different promoter/reporter constructs.
In our studies, two different fluorescent proteins allowed us to
monitor simultaneously the activity of two different promoters
during neuronal differentiation and therefore to track neurogen-
esis in living cells.
CONCLUSION
In summary, we describe the novel generation of 2K7 lentivec-
tors, which is particularly well suited for work with ES cells.
Key features include the possibility to select cell lines through
different antibiotic resistances and the rapid insertion of any
combination of promoters and genes of interest through recom-
binational cloning.
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